Table IV.
Key characteristics of CREATE-ECLA trial patients
| Baseline characteristic | CREATE |
ECLA | Overall | ||
|---|---|---|---|---|---|
| India | China | Pakistan | |||
| Number of patients | 8060 | 7510 | 827 | 3804 | 20,201 |
| Number of case report forms | 8060 | 7510 | 827 | 3798 | 20,195 |
| Age (mean & SD) | 55.5 (11.8) | 62.7 (11.9) | 55.4 (11.3) | 57.9 (12.4) | 58.6 (12.4) |
| % Males | 82.2 | 70.7 | 80.9 | 80.9 | 77.6 |
| Onset of symptoms to randomization (%) | |||||
| <6 Hours | 65.1 | 57.6 | 53.1 | 78.1 | 64.3 |
| 6–12 Hours | 34.9 | 42.1 | 46.9 | 20.9 | 35.4 |
| Median time (hours) | 4.5 | 5.2 | 5.7 | 3.7 | 4.7 |
| Previous MI (%) | 7.0 | 7.9 | 7.4 | 11.3 | 8.1 |
| Diabetes (%) | 22.8 | 11.2 | 23.9 | 18.6 | 17.7 |
| Hypertension (%) | 28.0 | 40.6 | 48.6 | 47.0 | 37.1 |
| Weight (kg) | 64.0 (10.6) | 66.5 (11.8) | 68.3 (9.8) | 77.4 (14.4) | 67.7 (12.8) |
| Blood pressure (mmHg) | 129.21/84.1 | 126.0/78.9 | 127.1/80.5 | 134.6/81.5 | 129.0 81.5 |
| Heart rate (beats/min) | 84.2 | 77.5 | 80.6 | 78.0 | 79.0 |
| Killip class >1 (%) | 14.4 | 18.1 | 10.9 | 12.2 | 15.4 |
| Mean glucose (mmol/L) | 9.1 (4.9) | 8.6 (4.3) | 9.2 (5.3) | 9.7 (4.7) | 9.0 (4.7) |
| Medications in hospital (%) | |||||
| Thrombolytic therapy | 91.9 | 52.5 | 89.7 | 75.3 | 74.1 |
| Direct PCI | 2.5 | 10.0 | 3.7 | 22.4 | 9.1 |
| Aspirin | 97.9 | 95.8 | 99.6 | 98.4 | 97.3 |
| Ticlopidine/clopidogrel | 80.2* | 27.8 | 78.6* | 16.0 | 48.6 |
| IV Nitrates | 59.4 | 91.8 | 60.6 | 70.2 | 73.5 |
| β-Blocker | 70.0 | 61.5 | 91.7 | 82.1 | 70.0 |
| ACE inhibitor | 73.6 | 71.7 | 85.5 | 68.2 | 72.4 |
| Lipid lowering | 62.3 | 71.3 | 88.0 | NR | NR |
| Calcium antagonist | 6.1 | 12.8 | 3.4 | 7.8 | 8.8 |
NR, Not recorded.
*
The high rates of use of a thienopyride is due to the availability of a combination tablet of aspirin + clopidogrel.